Operating Margin

Fortune Brands is reviewing its Fiberon decking unit, a move that could streamline its portfolio and reshape the competitive composite decking market.

A top financial forum is urging a GST hike, corporate tax cuts, and a radical revamp of retirement savings in its bold 2026 federal budget proposal.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

With booming revenue and a new premium product on the horizon, Grindr's CFO is set to outline the company's ambitious future to investors this month.

After unprecedented growth, Clear Fork Bank names a new CEO known for community ties, signaling a strategy to blend legacy values with future expansion.

Dream Finders Homes escalates its takeover attempt of Beazer Homes with a public offer, citing a decade of underperformance and a failing strategy.

As X Financial prepares its Q1 2026 results, investors are watching closely after a tough Q4 and amid China's harsh new fintech regulations.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

Celebrating a half-century of progress, Liberty Hill Foundation's anniversary gala was an urgent plea to fund the fight for Los Angeles's future.

CFO Martin Fischer's reappointment secures leadership continuity, reinforcing Fresenius Medical Care's focus on financial discipline and long-term growth.

SDEV reported a massive Q1 profit, but the real story is its unique strategy as a public DeFi holding company and the complex accounting behind the numbers.

Strong glaucoma sales and disciplined spending helped Iridex narrow its quarterly loss, signaling resilience despite retina segment woes and global headwinds.

Following a record year of profit and growth, the French diagnostics firm secures a major analyst endorsement, signaling a powerful turnaround. What's next?

Hyster launches the XTLG series, blending a rugged ICE chassis with lithium-ion power to bring electric efficiency to demanding outdoor applications.

With revenue hitting a record $47.6M, TerraCycle proves sustainability is profitable. But as it raises millions, can it overcome greenwashing critiques?

A top scientific honor for Dr. Mariano Garcia-Blanco validates a new approach to autoimmune disease, targeting a genetic trait in 50% of the population.

Newly public Yesway faces its first major test with its Q1 earnings. Investors will scrutinize if its aggressive expansion can meet high analyst expectations.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

Chinese machinery giant XCMG deepens its Belt and Road presence, betting that high-performance electric equipment will drive a value-based green shift.